DENTSPLY SIRONA (NASDAQ:XRAY) Director Michael Barber Buys 15,175 Shares of Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Michael Barber bought 15,175 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average cost of $9.88 per share, with a total value of $149,929.00. Following the purchase, the director directly owned 55,943 shares of the company’s stock, valued at approximately $552,716.84. This represents a 37.22% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

DENTSPLY SIRONA Trading Up 0.5%

Shares of XRAY stock opened at $10.14 on Tuesday. The stock has a 50-day simple moving average of $10.95 and a 200 day simple moving average of $11.71. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.40 and a fifty-two week high of $17.09. The stock has a market capitalization of $2.03 billion, a P/E ratio of -3.22, a P/E/G ratio of 1.20 and a beta of 0.89. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm had revenue of $880.00 million for the quarter, compared to the consensus estimate of $841.80 million. During the same period in the prior year, the business earned $0.43 EPS. The company’s quarterly revenue was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, sell-side analysts expect that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

XRAY has been the subject of several analyst reports. Wells Fargo & Company upped their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Weiss Ratings downgraded DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Zacks Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Barrington Research upped their target price on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Finally, Mizuho reduced their target price on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $13.55.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several hedge funds have recently modified their holdings of XRAY. Eurizon Capital SGR S.p.A. purchased a new stake in shares of DENTSPLY SIRONA during the fourth quarter valued at $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in DENTSPLY SIRONA in the 1st quarter worth about $26,000. Huntington National Bank lifted its stake in DENTSPLY SIRONA by 292.9% in the 3rd quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,077 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in DENTSPLY SIRONA by 119.1% in the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock worth $43,000 after acquiring an additional 2,051 shares in the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.